Title Category Credit Event datesort descending Cost
Precision Therapy in NSCLC: Pharmacist Perspectives on Testing Strategies and Biomarker-Driven Treatment Approaches
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00 Presented by CEC Oncology and supported through an independent educational grant from AstraZeneca.
New Horizons in HER2+ Breast Cancer: Pharmacist-Focused Strategies and Insights
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00 Presented by Creative Educational Concepts, Inc. (CEC) and supported through independent educational grants from AstraZeneca and Daiichi Sankyo.
Navigating a Changing Landscape in TNBC: Pharmacist-Focused Strategies in the Era of Immunotherapy
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00 Presented by Creative Educational Concepts, Inc. (CEC) and supported through an independent educational grant from Merck & Co., Inc.
EGFR Resisters Virtual Poster Walk
$0.00 We would like to provide patients, advocates, and others in the lung cancer community with a curated list of abstracts that may be of interest as you peruse the vast amount of data online at am.asco.org.
Anticoagulation Reversal for Life-threatening Bleeding: A Case-based Presentation for the Critical Care Team
  • Cardiology
$0.00 Click here to complete this activity 
Pharmacist Perspectives: Exploring the Evolving Role of BTK Inhibitors in CLL
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00 Participants will gain exposure to emerging clinical and scientific advances in the treatment of chronic lymphocytic leukemia (CLL) with BTK inhibitors (BTKis), including novel pharmacologic targets within the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for BTK inhibitors in both treatment-naïve (TN) and relapsed/refractory (R/R) CLL. Prominent mechanisms of BTK inhibitor resistance and adaptive strategies used to prevent and/or mitigate the development of resistance also will be explored.
Managing Cardiovascular Disease in the Time of COVID-19
  • AMA PRA Category 1 Credit™
  • Participation
$0.00 As the novel coronavirus, SARS-CoV-2, spreads across the globe, and as confirmed cases of COVID-19 infection continue to climb, we are being ushered into circumstances which are unprecedented in modern times. It is thus absolutely vital that cardiologists, who are tasked with managing a patient population with chronic cardiovascular disease (CVD) that is, resultantly, at high risk for severe manifestations of COVID-19, be informed regarding adaptive ways to maintain effective CVD disease management while also keeping their patients safe.
Oncology Clinical Briefing: Expert Insights for Managing Bladder Cancer in the Time of COVID-19
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00 As the novel coronavirus, SARS-CoV-2, spreads across the globe, and as confirmed cases of COVID-19 infection continue to climb, we are being ushered into circumstances which are unprecedented in modern times. It is thus absolutely vital that oncology clinicians, who manage a patient population at very high risk for severe manifestations of COVID-19, be informed regarding adaptive ways to keep their patients safe. To help meet that need, this online educational activity will review the ever-changing epidemiology of COVID-19 and identify primary infection risk concerns for cancer patients.
Oncology Clinical Briefing: Expert Insights for Managing Breast Cancer in the Time of COVID-19
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00 As the novel coronavirus, SARS-CoV-2, spreads across the globe, and as confirmed cases of COVID-19 infection continue to climb, we are being ushered into circumstances which are unprecedented in modern times. It is thus absolutely vital that oncology clinicians, who manage a patient population at very high risk for severe manifestations of COVID-19, be informed regarding adaptive ways to keep their patients safe. To help meet that need, this online educational activity will review the ever-changing epidemiology of COVID-19 and identify primary infection risk concerns for cancer patients.
Best Practices for Using Long-acting Injectable Antipsychotics during COVID-19
  • Psychiatry
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
$0.00 In recent years, the landscape for the treatment of severe mental illness such as schizophrenia has evolved with increasing use of long-acting injectable antipsychotics (LAIs) as new data tout significant benefits of these agents over oral treatment. Early randomized, controlled trials did not show superiority of LAIs over oral antipsychotics. However, in recent years, overwhelming evidence suggests that LAIs may improve adherence, reduce relapse and hospitalizations, lessen the risk of treatment failure, and decrease mortality.

Pages